Clinical trials: Antiviral Treatment
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of combination zidovudine (AZT) and PMEA (adefovir) therapy.
- Trial name
- NCT00002326
- Testing
- Adefovir, Zidovudine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts
The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP.
- Trial name
- NCT00000908
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Hepatitis B
Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar
The project will evaluate cost and treatment outcomes of a simplified hepatitis C virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations including people who inject…
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- NCT03579576
- Testing
- sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.
- Where
- 3 sites in Burma
- Volunteers
- 803 people
- Sponsor
- Right to Care
Ulcerative Colitis, Unspecified
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
Ulcerative Colitis (UC) is an inflammatory bowel disease that can require the use of anti-TNF alpha therapy. When anti-TNF alpha failed to obtain a clinical response, the use of a new anti-integrin therapy, vedolizumab, can be…
- Trial name
- CYTOVEDO (NCT04064697)
- Testing
- Valganciclovir
- Where
- 8 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hepatitis C Virus
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
- Trial name
- PEG-IFN-SA (NCT01605513)
- Testing
- interferon
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Hospital of Jilin University
Hepatitis C
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously…
- Trial name
- POLARIS-1 (NCT02607735)
- Testing
- SOF/VEL/VOX
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 416 people
- Sponsor
- Gilead Sciences
COVID-19
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms…
- Trial name
- FLARE (NCT04499677)
- Testing
- Favipiravir, Lopinavir/ Ritonavir
- Where
- 2 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- University College, London
Hepatitis B Virus
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
The purpose of this study is to evaluate the safety and immunotherapeutic activity of cemiplimab in participants with hepatitis B virus (HBV) on suppressive antiviral therapy.
- Trial name
- NCT04046107
- Testing
- Cemiplimab
- Where
- 8 sites in United States, Brazil and 2 more
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
The purpose of this study is to compare the effectiveness of taking didanosine (ddI) once a day plus stavudine (d4T) twice a day with taking ddI twice a day plus d4T twice a day.
- Trial name
- NCT00002207
- Testing
- Stavudine, Didanosine
- Where
- 13 sites in United States
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Hepatitis C, Chronic
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Background: Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people.
- Conditions
- Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
- Trial name
- NCT03520660
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infection
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients
The purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of Kaletra single agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of…
- Trial name
- MONARK (NCT00234923)
- Testing
- lopinavir/ritonavir, lamivudine/zidovudine
- Volunteers
- 138 people
- Sponsor
- Abbott
COVID-19
Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19
This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days…
- Trial name
- NCT04536090
- Testing
- Isoquercetin (IQC-950AN)
- Sponsor
- Institut de Recherches Cliniques de Montreal
Covid19
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms…
- Trial name
- FANTAZE (NCT04918927)
- Testing
- Favipiravir, Nitazoxanide
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
HCV Infection, Liver Cirrhosis, Experimental
Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation
Evaluation of efficacy of triple therapy with pegylated interferon, ribavirin, and boceprevir in patients with genotype 1 chronic hepatitis C, who are treatment-naive, have relapsed, or are non-responders with cirrhosis and…
- Trial name
- NCT01463956
- Testing
- Boceprevir, Peg-Interferon α-2b or Peg-Interferon α-2a, Ribavirin
- Where
- 19 sites in France
- Volunteers
- 58 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C, Chronic
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have…
- Trial name
- NCT01168856
- Where
- 126 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Long-Term Lamivudine Therapy for Chronic Hepatitis B
This study will evaluate the long-term safety and effectiveness of lamivudine therapy and the possibility of stopping therapy in patients whose hepatitis B is chronic, that is, long lasting, and which has responded to treatment.
- Trial name
- NCT00120354
- Testing
- Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
SARS-CoV Infection, Covid19
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus.
- Trial name
- TriACT (NCT04605588)
- Testing
- Nitazoxanide, Ribavirin, Hydroxychloroquine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
HIV Infections
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
To assess the safety and to evaluate the anti-HIV effect of low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients.
- Trial name
- NCT00000656
- Testing
- Zidovudine, Didanosine
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of 141W94 and Indinavir in HIV-Infected Patients
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks.
- Trial name
- NCT00002202
- Testing
- Indinavir sulfate, Amprenavir
- Where
- 24 sites in United States
- Volunteers
- 460 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.
- Trial name
- NCT00000872
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)